NIDDM in patients inadequately controlled on diet alone, or on diet & oral hypoglycaemic agents. Prevention of onset of NIDDM in patients w/ impaired glucose tolerance & impaired fasting glycaemia, in combination w/ diet & exercise.
AdultTreatment Initially 50 mg tds, may be increased to 100 mg tds after 6-8 wk, if necessary. Max dose: 200 mg tds. To minimize GI side-effects, initially 50 mg once daily or bd, titrated to tds regimen. Prevention Initially 50 mg daily, subsequently increased to 100 mg tds after 4-8 wk. Patient w/ ≤60 kg body wt 50 mg tds.
View Glucobay overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food: Take w/ 1st bite of a main meal.
Contraindications
Hypersensitivity. Patients w/ inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or patients predisposed to intestinal obstruction; chronic intestinal diseases associated w/ marked disorders of digestion or absorption; conditions which may deteriorate as a result of increased gas formation in the intestine (eg, larger hernias). Severe hepatic impairment. Severe renal impairment (CrCl <25 mL/min/1.73 m2). Pregnancy & lactation.
Risk of hypoglycaemia w/ other blood glucose lowering drugs (eg, sulphonylureas: metformin, or insulin); should not be corrected using disaccharides (sucrose). Consider liver enzyme monitoring during the 1st 6-12 mth of treatment. Reduce dose or discontinue use in case of persistent liver enzyme elevations. Use of Mg- & Al-containing antacid prep (eg, hydrotalcite) to treat acute GI symptoms of Glucobay is not recommended. Childn & adolescents <18 yr.
Sign Out
